NCT06638931 2026-04-15ANTARESInstituto do Cancer do Estado de São PauloPhase 2 Recruiting28 enrolled
NCT04278144 2025-09-15A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid TumorsBolt Biotherapeutics, Inc.Phase 1/2 Terminated175 enrolled